Aberdeen Group plc Acquires 60,188 Shares of Janux Therapeutics, Inc. $JANX

Aberdeen Group plc grew its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 21.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 345,476 shares of the company’s stock after purchasing an additional 60,188 shares during the period. Aberdeen Group plc owned about 0.57% of Janux Therapeutics worth $8,443,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Profund Advisors LLC raised its stake in shares of Janux Therapeutics by 63.5% during the third quarter. Profund Advisors LLC now owns 16,438 shares of the company’s stock valued at $402,000 after acquiring an additional 6,386 shares during the last quarter. SG Americas Securities LLC grew its stake in Janux Therapeutics by 247.8% in the third quarter. SG Americas Securities LLC now owns 29,015 shares of the company’s stock valued at $709,000 after acquiring an additional 20,673 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in Janux Therapeutics during the third quarter worth $207,000. Congress Asset Management Co. bought a new position in Janux Therapeutics in the 3rd quarter valued at about $1,363,000. Finally, Osaic Holdings Inc. boosted its position in shares of Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after buying an additional 3,037 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

JANX stock opened at $13.08 on Friday. The business has a fifty day moving average price of $13.80 and a 200-day moving average price of $21.08. The stock has a market capitalization of $786.76 million, a P/E ratio of -7.79 and a beta of 2.88. Janux Therapeutics, Inc. has a 1-year low of $12.12 and a 1-year high of $38.42.

Insider Transactions at Janux Therapeutics

In other news, insider Charles M. Winter sold 2,401 shares of Janux Therapeutics stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $32,965.73. Following the sale, the insider directly owned 77,721 shares of the company’s stock, valued at approximately $1,067,109.33. The trade was a 3.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Thomas Diraimondo sold 2,505 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $34,393.65. Following the sale, the insider directly owned 124,425 shares in the company, valued at $1,708,355.25. This trade represents a 1.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 22,366 shares of company stock valued at $371,245. Company insiders own 8.10% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on JANX. Bank of America dropped their price target on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Cantor Fitzgerald lowered their target price on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 2nd. Clear Str downgraded Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Piper Sandler reduced their price target on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a research report on Friday, January 16th. Finally, Stifel Nicolaus dropped their price objective on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, December 2nd. Eleven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $60.08.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.